Kairos Pharma Q&A: Waging the War on Cancer Drug Resistance
Reversing Cancer Drug Resistance: Kairos Pharma’s Vision
Commercial Insight – Cancer cells often outsmart therapies, evolving resistance through genetic, epigenetic, and environmental tweaks. Kairos Pharma, under Dr. John Yu’s leadership, targets this resilience head‑on by attacking the protein CD‑105, a key switch that steers tumors toward a drug‑tolerant, stem‑like state.
About Kairos Pharma & Dr. John Yu
- Founded by a neurosurgeon with 25 years of research in brain tumors and immunotherapy.
- Designs targeted therapies to re‑sensitize cancer cells while amplifying the immune response.
- Focuses on early intervention to halt the molecular shift that leads to resistance.
Why CD‑105 Matters
After standard treatment, many tumors spike CD‑105 expression, correlating with an enrichment of cancer stem‑like cells—resilient, aggressive, and hard to kill. Blocking CD‑105 restores sensitivity to both chemotherapy and checkpoint inhibitors.
USP of Kairos’s Approach
- Not a conventional cytotoxic drug; it remodels the tumor environment.
- Works in conjunction with existing therapies, extending their efficacy.
- Aims for permanent reversal of resistance rather than temporary solutions.
Current Clinical Focus
- Prostate cancer – one of the most frequent cancers with stubborn resistance.
- Non‑small cell lung cancer – notorious for losing response to targeted and immune therapies.
Preclinical data already show CD‑105 overexpression in breast, colon, and head‑and‑neck cancers, hinting at a broader platform potential.
Regulatory & Development Roadmap
Key milestones: Phase 1/2 trials in prostate and lung cancers, safety profiling, and intensive data on progression‑free survival.
Challenges include quantifying resistance as a primary endpoint and proving sustained benefit over time.
Outlook for the Next 3–5 Years
- Transition from preclinical to early clinical studies.
- Publish new preclinical results and present at major oncology conferences.
- Scale to additional tumor types and explore combinations with chemotherapy and checkpoint inhibitors.
- Leverage partnerships and investment to push toward commercialization.
By confronting the root of drug resistance, Kairos Pharma aims to redefine treatment failure and pave the way for durable cancer control.
